COVID-19 Shipping Update

There are delays in the postal system, please order early. More information is here.

Shipping delays due to Covid-19 Virus

Please fill the form to receive updates when we can ship your order.

Combination HRT

Our Combination HRT class of Womans/HRT medications contain a combination of a progestogen and an oestrogen used for hormone replacement therapy, to help relieve symptoms of menopause while at the same time counteracting the potentially harmful effects of estrogen alone.

Use the search feature to quickly find the product you are looking for by entering either the active ingredient, e.g. Norethisterone or the product name e.g. Kliogest.

Our Combination HRT class of Womans/HRT medications contain a combination of a progestogen and an oestrogen used for hormone replacement therapy, to help relieve symptoms of menopause while at the same time counteracting the potentially harmful effects of estrogen alone.

Use the search feature to quickly find the product you are looking for by entering either the active ingredient, e.g. Norethisterone or the product name e.g. Kliogest.
...Read more

Duavive (Conjugated Estrogens/Bazedoxifene 0.45mg/20mg) 28 Tablets/Pack
Duavive (Conjugated Estrogens/Bazedoxifene)
Conjugated Estrogens/Bazedoxifene
Also known as Duavee
Out Of Stock
Kliogest 28 Tablets/Pack
Kliogest
Oestradiol 2mg /Norethisterone 1mg
From $1.44 per Tablet
Kliovance 28 Tablets/Pack
Kliovance
Estradiol 1mg/norethisterone acetate 0.5mg
Out Of Stock
Premia 2.5 Continuous 28 Tablets/Pack
Premia 2.5 Continuous
Conjugated Oestrogens 0.625mg/Medroxyprogesterone 2.5mg
Also known as Prempro
Discontinued
Premia 5 Continuous 28 Tablets/Pack
Premia 5 Continuous
Conjugated Oestrogens 0.625mg/Medroxyprogesterone 5mg
Also Known as Prempro
Discontinued

Risks of estrogen only versus combination HRT

Hormone replacement therapy (HRT) is used to help relieve symptoms of menopause by replacing female hormones that the body has stopped making naturally.  Most widely used forms of HRT are estrogen only and can be used by women with or without a uterus.  However, postmenopausal women who have not had a hysterectomy may be at risk of endometrial cancer after long-term HRT, due to continued action of oestrogen on the endometrium.

Oestrogen stimulates growth and proliferation of the endometrium and without the normal hormonal balance provided by progesterone, this stimulation by oestrogen can lead to excessive proliferation of the endometrial cells or endometrial hyperplasia, which increases risk of endometrial carcinoma.  The addition of a progestogen (natural or synthesised progesterone) counteracts the stimulatory effect of oestrogen, acting in a similar way to natural progesterone.

However, there is some evidence that oestrogen plus progestin can increase risk of breast cancer and ovarian cancer.  With more published studies more evidence is available to assess the relative risks of various forms of HRT.1-3 Opinion regarding  Oestrogen only HRT are also changing and it is now thought that Oestrogen only HRT does not increase risk of breast cancer or substantially interfere with breast cancer detection by mammography. 3

Types of combination HRT

Combination HRT is available as tablets comprising combination of various forms of Oestrogen and progestin, including:

  • Conjugated Oestrogens and Medroxyprogesterone 
  • Oestradiol and Norethisterone

References

  1. Campagnoli C, Clavel-Chapelon F, Kaaks R, Peris C, Berrino F.  Progestins and progesterone in hormone replacement therapy and the risk of breast cancer.  J Steroid Biochem Mol Biol 2005: 96; 95-108.
  2. Chlebowski RT, Manson JE, Anderson GL, Cauley JA, Aragaki AK, Stefanick ML, Lane DS, Johnson KC, Wactawski-Wende J, Chen C, Qi L, Yasmeen S,Newcomb PA, Prentice RL. Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study.  J Natl Cancer Inst. 2013: 105; 526-35.
  3. Chlebowski RT andGarnet L. Anderson GL.  Changing Concepts: Menopausal Hormone Therapy and Breast Cancer. J Natl Cancer Inst. 2012: 104; 517-27. 
...Read more

Risks of estrogen only versus combination HRT

Hormone replacement therapy (HRT) is used to help relieve symptoms of menopause by replacing female hormones that the body has stopped making naturally.  Most widely used forms of HRT are estrogen only and can be used by women with or without a uterus.  However, postmenopausal women who have not had a hysterectomy may be at risk of endometrial cancer after long-term HRT, due to continued action of oestrogen on the endometrium.

Oestrogen stimulates growth and proliferation of the endometrium and without the normal hormonal balance provided by progesterone, this stimulation by oestrogen can lead to excessive proliferation of the endometrial cells or endometrial hyperplasia, which increases risk of endometrial carcinoma.  The addition of a progestogen (natural or synthesised progesterone) counteracts the stimulatory effect of oestrogen, acting in a similar way to natural progesterone.

However, there is some evidence that oestrogen plus progestin can increase risk of breast cancer and ovarian cancer.  With more published studies more evidence is available to assess the relative risks of various forms of HRT.1-3 Opinion regarding  Oestrogen only HRT are also changing and it is now thought that Oestrogen only HRT does not increase risk of breast cancer or substantially interfere with breast cancer detection by mammography. 3

Types of combination HRT

Combination HRT is available as tablets comprising combination of various forms of Oestrogen and progestin, including:

  • Conjugated Oestrogens and Medroxyprogesterone 
  • Oestradiol and Norethisterone

References

  1. Campagnoli C, Clavel-Chapelon F, Kaaks R, Peris C, Berrino F.  Progestins and progesterone in hormone replacement therapy and the risk of breast cancer.  J Steroid Biochem Mol Biol 2005: 96; 95-108.
  2. Chlebowski RT, Manson JE, Anderson GL, Cauley JA, Aragaki AK, Stefanick ML, Lane DS, Johnson KC, Wactawski-Wende J, Chen C, Qi L, Yasmeen S,Newcomb PA, Prentice RL. Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study.  J Natl Cancer Inst. 2013: 105; 526-35.
  3. Chlebowski RT andGarnet L. Anderson GL.  Changing Concepts: Menopausal Hormone Therapy and Breast Cancer. J Natl Cancer Inst. 2012: 104; 517-27. 
...Read more

 

This website uses cookies. View our policy and select your preferences here